Electrophysiology

EQS-News: Volta Medical Announces Late-Breaking TAILORED-AF Randomized Clinical Trial Results at Heart Rhythm 2024 in Boston, MA, USA

Retrieved on: 
星期五, 五月 3, 2024
Atrial fibrillation, Loyola University Medical Center, Ecosystem, AI, Poster, Heart, Machine learning, Artificial intelligence, Artificiality, Communication, Environment, Data collection, PVI, Arrhythmia, Collection, Rhythm, Clinical trial, Electrophysiology, Catheter, Northwell Health, Medical device

This AI companion technology may help electrophysiologists to optimize catheter-ablation procedures for complex arrhythmias, including persistent AF.

Key Points: 
  • This AI companion technology may help electrophysiologists to optimize catheter-ablation procedures for complex arrhythmias, including persistent AF.
  • Professor Isabel Deisenhofer will share findings from the TAILORED-AF clinical trial.
  • Volta Medical is hosting a Rhythm Theater presentation, “The Future of AI Implementation in AF Ablation Procedures”.
  • Volta Medical will exhibit at booth #328, featuring a demonstration of the Volta AF-Xplorer™ software, while a tech suite at #TS266 will spotlight the company’s product vision.

Integer Holdings Corporation Reports First Quarter 2024 Results

Retrieved on: 
星期四, 四月 25, 2024
Neuromodulation, Arrhythmia, Growth, Acquisition, EPS, PMA, GAAP, Electrophysiology, Electrochemistry

PLANO, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 29, 2024.

Key Points: 
  • PLANO, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 29, 2024.
  • First Quarter 2024 Highlights (compared to First Quarter 2023, except as noted)
    Sales increased 10% to $415 million, with organic growth of 6%.
  • Cardiac Rhythm Management & Neuromodulation sales increased 8% in the first quarter 2024 compared to the first quarter 2023, with strong growth in emerging Neuromodulation customers with PMA (pre-market approval) products and strong demand in Cardiac Rhythm Management.
  • Electrochem sales decreased in the first quarter 2024 compared to the first quarter 2023, returning to a normalized run-rate after previously higher sales from the supply chain recovery.

Dobson family gift to Driscoll marks new era for nationally recognized heart program

Retrieved on: 
星期三, 四月 24, 2024
Society, Interview, Laboratory, Hospital, Dobson, Risk, Cardiology, Survival, Heart, Christi, O'Driscoll (surname), Family, Patient, Operating, Electrophysiology, Growth, Cardiac catheterization, Pavilion

Corpus Christi, Texas, April 24, 2024 (GLOBE NEWSWIRE) -- Driscoll Children’s Hospital is celebrating a multimillion dollar gift by the Dobson Family Foundations, Las Aguilas Enterprises, and individual Dobson family members to support its Heart Center, a nationally recognized pediatric cardiac program that treats children and newborns with the most complex congenital heart diseases.

Key Points: 
  • Corpus Christi, Texas, April 24, 2024 (GLOBE NEWSWIRE) -- Driscoll Children’s Hospital is celebrating a multimillion dollar gift by the Dobson Family Foundations, Las Aguilas Enterprises, and individual Dobson family members to support its Heart Center, a nationally recognized pediatric cardiac program that treats children and newborns with the most complex congenital heart diseases.
  • Furthermore, the historic gift will establish the Harmon and Grace Dobson Distinguished Chair in Cardiac Surgery, the first of its kind at Driscoll and in South Texas.
  • In honor of the Dobson family’s everlasting gift, the fourth floor of the Pavilion will be named the Dobson Family Cardiac Suite.
  • Driscoll is grateful to the Dobson family for their faith in and commitment to our mission,” said Driscoll President and CEO Eric Hamon.

Volta Medical Announces Presentations at Heart Rhythm Society 2024 in Boston, MA, USA

Retrieved on: 
星期四, 四月 18, 2024
Loyola University Medical Center, Ecosystem, Poster, Heart, Machine learning, Communication, Environment, Northwell Health, Data collection, Arrhythmia, Collection, Atrial fibrillation, Rhythm, Electrophysiology

MARSEILLE, France, April 18, 2024 (GLOBE NEWSWIRE) -- Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists in assessing complex cardiac arrhythmias such as atrial fibrillation (AF), today announced presentations to be made at the Heart Rhythm Society 2024 meeting in Boston, May 16 to 19. In-person attendance and live online participation in a hybrid format will be available. Volta will host a demonstration of Volta AF-Xplorer™, and a Rhythm Theater featuring a panel of experts in the field moderated by Dr. Andrea Natale, a leading cardiac electrophysiologist at the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, TX.

Key Points: 
  • Volta’s AF-Xplorer identifies and annotates unique abnormalities (spatiotemporal dispersed electrograms) on 3D anatomical and electrical maps of the heart.
  • This AI companion technology may help electrophysiologists to optimize catheter-ablation procedures for complex arrhythmias, including persistent AF.
  • Volta Medical is hosting a Rhythm Theater presentation, “The Future of AI Implementation in AF Ablation Procedures”.
  • Volta Medical will exhibit at booth #328, featuring a demonstration of the Volta AF-Xplorer software, while a tech suite at #TS266 will spotlight the company’s product vision.

Metrion Biosciences Enhances High Throughput Screening Services With Access to Enamine Compound Libraries

Retrieved on: 
星期四, 四月 11, 2024
Research, Technology, Medical Devices, Other Technology, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Other Science, Penta, Safety, REAL, Projection screen, Library, CNS, HTS, Drug discovery, Electrophysiology

Metrion Biosciences Limited (“Metrion”), the specialist ion channel and cardiac safety screening contract research organisation (CRO) and drug discovery company, and Enamine Ltd (“Enamine”), the global leader in supplying small molecules and early drug discovery services, announced that Metrion has enhanced its High Throughput Screening (HTS) services with the addition of access to Enamine’s compound libraries.

Key Points: 
  • Metrion Biosciences Limited (“Metrion”), the specialist ion channel and cardiac safety screening contract research organisation (CRO) and drug discovery company, and Enamine Ltd (“Enamine”), the global leader in supplying small molecules and early drug discovery services, announced that Metrion has enhanced its High Throughput Screening (HTS) services with the addition of access to Enamine’s compound libraries.
  • The Enamine compound library collection is the largest in the world and includes both CNS and ion channel focused target libraries.
  • The libraries can be split into discrete screening sets, enabling increased flexibility and efficiencies in screening and target identification.
  • We are delighted that Metrion is adding access to our libraries to its HTS services offering.

Acutus Medical Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期一, 四月 1, 2024
AFIB, Research, Classification, Sale, Electrophysiology, Medtronic, 2012 Six-red World Championship, GAAP, Operation, Marketing, Video game

CARLSBAD, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the fourth quarter and full year ended December 31,2023.

Key Points: 
  • CARLSBAD, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the fourth quarter and full year ended December 31,2023.
  • Announced strategic realignment of resources and corporate restructuring on November 8, 2023 with the objective of optimizing financial position and maximizing free cash flow.
  • Fourth quarter revenue from Continuing Operations of $2.4 million grew 118% year-over-year, from $1.1 million in the year ago fourth quarter.
  • Revenue from Continuing Operations was $2.4 million for the fourth quarter of 2023, an increase of 118% compared to $1.1 million for the fourth quarter of 2022.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system

Retrieved on: 
星期二, 四月 9, 2024
Electrophysiology, St Davids, Atrial fibrillation, Arrhythmia, Patient, PFA, Medical Center, Quality of life, FDA, Food, Medical device

The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.

Key Points: 
  • The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.
  • Dr. Natale and Dr. Al-Ahmad were two of 67 global operators to participate in the trial that led to FDA approval.
  • The novel PFA system delivers short-duration, high-energy electrical pulses to the cardiac tissue to destroy cells that cause irregular heart rhythms without using excess heat or cold.
  • "Our team is honored to have played a part in piloting this new era of global innovation for cardiac arrhythmia."

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system

Retrieved on: 
星期二, 四月 9, 2024
Electrophysiology, St Davids, Atrial fibrillation, Arrhythmia, Patient, PFA, Medical Center, Quality of life, FDA, Food, Medical device

The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.

Key Points: 
  • The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.
  • Dr. Natale and Dr. Al-Ahmad were two of 67 global operators to participate in the trial that led to FDA approval.
  • The novel PFA system delivers short-duration, high-energy electrical pulses to the cardiac tissue to destroy cells that cause irregular heart rhythms without using excess heat or cold.
  • "Our team is honored to have played a part in piloting this new era of global innovation for cardiac arrhythmia."

Mount Sinai Is First in New York to Test Revolutionary Brain-Computer Implant Designed to Map Brain Activity in Unprecedented Detail

Retrieved on: 
星期五, 三月 22, 2024
Principal, Electric potential, Speech, Culture, Brain, BCI, Health, Assistant, Associate, Patient, DSM-IV codes, Research, Electrophysiology, Doctor of Philosophy, Translation, MD, Quality of life, Science, Behavior, Mount Sinai Health System, Medical imaging

A brain-computer interface (BCI) is a system that deciphers brain signals and translates them into commands for external technologies.

Key Points: 
  • A brain-computer interface (BCI) is a system that deciphers brain signals and translates them into commands for external technologies.
  • The film is one-fifth the thickness of a human hair and was designed to be implanted and removed by neurosurgeons without damaging brain tissue.
  • Dr. Rapoport also serves as the Scientific Director of Mount Sinai BioDesign, a medical technology prototyping center and incubator housed within the Mount Sinai Health System.
  • All Precision Neuroscience research at Mount Sinai is conducted by independent investigators without financial ties to the company.

Autonomix Appoints Jennifer Cook as Chief Business Officer

Retrieved on: 
星期二, 三月 19, 2024
AbbVie, Growth, Health, Miami University, Real Chemistry, Nervous system, Business administration, Integration, Adjustable gastric band, Research, Class, Marketing communications, Jennifer Cook, Electrophysiology, Record, Translation, Marketing, Cellulite, Advertising, AMIX, Management

THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer.

Key Points: 
  • Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated companies.
  • “We are very pleased to welcome Jennifer to the Autonomix team.
  • Her expertise in business strategy and analysis will be of great value as we continue to execute on our corporate and clinical efforts moving forward.
  • Mrs. Cook holds a Bachelor of Science in Business Administration and Marketing from Miami University, Oxford, Ohio.